FluQuadri

Main information

  • Trade name:
  • FluQuadri Junior Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin 30mcg, 0.25mL suspens
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • FluQuadri Junior Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin 30mcg, 0.25mL suspens
    Australia
  • Language:
  • English

Other information

Status

  • Source:
  • Dept. of Health,Therapeutic Goods Administration - Australia
  • Authorization number:
  • 213964
  • Last update:
  • 09-10-2017

Public Assessment Report

Public Summary

Summary for ARTG Entry:

213964

FluQuadri Junior Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin

30mcg, 0.25mL suspension for injection

ARTG entry for

Medicine Registered

Sponsor

Sanofi-Aventis Australia Pty Ltd

Postal Address

Locked Bag 2227,NORTH RYDE BC, NSW, 1670

Australia

ARTG Start Date

2/12/2014

Product category

Medicine

Status

Active

Approval area

Drug Safety Evaluation Branch

Conditions

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods

Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered

or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Products

1. FluQuadri Junior Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin

30mcg, 0.25mL suspension for injection 2017

Product Type

Single Medicine Product

Effective date

20/07/2017

Warnings

See Product Information and Consumer Medicine Information for this product

Standard Indications

Specific Indications

FluQuadri and FluQuadri Junior are indicated for active immunisation of influenza disease caused by influenza A subtype viruses and type B viruses

contained in the vaccine.

FluQuadri is indicated for use in adults and children 3 years and older.

FluQuadri Junior is indicated for use in children aged 6 months to 35 months inclusive.

Additional Product information

Container information

Type

Material

Life Time

Temperature

Closure

Conditions

Syringe

Glass Type I Clear

12 Months

Store at 2 to 8

degrees Celsius

Neither child resistant

closure nor restricted

flow insert

Do not Freeze

Pack Size/Poison information

Pack Size

Poison Schedule

5 syringes per pack

(S4) Prescription Only Medicine

10 syringes per pack

(S4) Prescription Only Medicine

Components

1. FluQuadri Junior Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin 30mcg, 0.25mL suspension for

injection

Dosage Form

Injection, suspension

Route of Administration

Intramuscular

Visual Identification

Clear and slightly opalescent in colour

Active Ingredients

Influenza virus haemagglutinin

7.5 microgram

Influenza virus haemagglutinin

7.5 microgram

Influenza virus haemagglutinin

7.5 microgram

Influenza virus haemagglutinin

7.5 microgram

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

Public Summary

Page 1 of

Produced at 26.11.2017 at 10:41:54 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information

Patient Information leaflet

FluQuadri™;

FluQuadri™ Junior

Inactivated Quadrivalent Influenza Vaccine (Split Virion)

Consumer Medicine Information

What is in this leaflet

Read all of this leaflet carefully

before you are vaccinated.

Keep this leaflet. You may need

to read it again.

If you have any further questions,

ask your doctor or pharmacist.

This vaccine has been prescribed

for you. Do not pass it on to

others.

If any of the side effects gets

serious, or if you notice any side

effects not listed in this leaflet,

please tell your doctor or

pharmacist.

In this leaflet:

What FluQuadri/FluQuadri Junior

are and what they are used for

Before you are given FluQuadri/

FluQuadri Junior

How FluQuadri/FluQuadri Junior

are given

Possible side effects

Storing FluQuadri/FluQuadri

Junior

Further information

What FluQuadri/

FluQuadri Junior are

and what they are

used for

FluQuadri and FluQuadri Junior are

vaccines. Vaccines are used to

protect you against infectious

diseases.

FluQuadri and FluQuadri Junior are

recommended to help protect you

against influenza. FluQuadri may be

administered to persons aged 36

months and older, especially who run

an increased risk of influenza-

associated complications. FluQuadri

Junior is designed for use in children

aged 6 to 35 months.

Influenza (flu) is a disease caused by

different types of virus. Influenza

viruses can spread rapidly, especially

in homes or institutions, where it can

be very easy for someone to catch flu

and spread the disease. The greatest

risk of catching flu is during the cold

months between May and October.

Your doctor will be able to

recommend the best time for you to

be vaccinated. Flu is present every

year, even when epidemics or

outbreaks are not reported.

The vaccine will only help to prevent

flu if it is caused by one of the four

strains of virus contained in the

vaccine, or other strains closely

related to them. FluQuadri/FluQuadri

Junior will not prevent flu if you are

incubating the disease before

vaccination or if it is caused by

another virus.

You should also note that many

germs can cause influenza-like

illness and the vaccine will not

protect you against these.

Previous injections of flu vaccine are

unlikely to give you protection

against the current strains of flu virus

which are most common this year, so

you will need to receive a vaccine

against flu every year especially if

you are at risk.

How They Work

FluQuadri and FluQuadri Junior

work by helping the body to make

antibodies. These antibodies help the

body to recognise the flu virus and

prevent the infection. It takes a few

weeks for the body to produce these

antibodies. The vaccine will protect

you only against the influenza

viruses contained in the vaccine (or

other strains closely related to them).

It will not protect you from viruses

that are unrelated to those contained

in the vaccine.

Before you are given

FluQuadri/FluQuadri

Junior

When you or your child

must not be given it

Do not have FluQuadri/FluQuadri

Junior

If you or your child ever had a

severe allergic reaction to:

Eggs or egg products

Any of the other ingredients of

FluQuadri/FluQuadri Junior listed

in the FURTHER

INFORMATION section.

If you or your child ever had a

severe allergic reaction after

getting any flu vaccine.

Before speaking to your doctor, if

you or your child has an acute

illness with or without high

temperature.

FLUQUADRI™; FLUQUADRI™ JUNIOR

Take special care with

FluQuadri/FluQuadri Junior

Tell your doctor if you or your

child has or has had Guillain-

Barré syndrome (severe muscle

weakness) after getting a flu

vaccine

Tell your doctor if you or your

child has or has had an immune

response problem because the

immune response to the vaccine

may be diminished

Tell your doctor if you are

pregnant or breast feeding.

Your doctor will discuss the possible

risks and benefits of having

FluQuadri during pregnancy or

breastfeeding. Sanofi Pasteur is

collecting information on pregnancy

outcomes and the health of newborn

following vaccination with

FluQuadri during pregnancy. Women

who receive FluQuadri during

pregnancy are encouraged to contact

Sanofi Pasteur directly or have their

doctor contact Sanofi Pasteur at 1800

829 468 (in Australia) or 0800 727

838 (in New Zealand)

Your doctor should make sure the

benefits of vaccination outweigh the

risks when recommending

FluQuadri/FluQuadri Junior.

Taking other medicines

Medicines that may reduce your

immune response: such as

corticosteroids (for example

prednisone), medicines used to

treat cancer (chemotherapy),

radiotherapy or other medicines

affecting the immune system. Tell

your doctor if you have been

treated with such medicines.

Please tell your doctor or

pharmacist if you are taking or

have recently taken any other

medicines, including medicines

obtained without prescription.

Having other vaccines

Your doctor will advise you if

FluQuadri/FluQuadri Junior is to

be given with another vaccine.

How FluQuadri/

FluQuadri Junior are

given

FluQuadri/FluQuadri Junior is

administered to you by your doctor

or your nurse.

Dose and Schedule

Adults and children over 35 months:

A single 0.5 mL injection

Children 6 to 35 months: A single

0.25 mL injection

Some children require a second

injection a month later.

Method of Administration

FluQuadri/FluQuadri Junior is

injected into the muscles of the upper

arm (preferably). For infants, the

injection is normally given into the

muscle of the thigh.

Possible side effects

Like all medicines, FluQuadri/

FluQuadri Junior can cause side

effects, although not everybody gets

them.

The most common local side effects

of FluQuadri/FluQuadri Junior

include:

pain, tenderness, redness

(erythema), swelling, bruising

(ecchymosis) and hardness

(induration) at the injection site

Systemic side effects include:

feeling unwell (malaise)

muscle aches (myalgia)

headache

shivering

fever

irritability, abnormal crying,

drowsiness, appetite loss,

vomiting (in children)

These side effects usually clear up

within a few days. If events

continue or become severe, please

tell your doctor or pharmacist.

Other side effects not listed above

have been reported occasionally with

other flu vaccines and not directly

with FluQuadri/FluQuadri Junior:

inflammation of nerves leading to

weakness, such as weakness of

facial muscles (facial palsy) or

visual disturbances (optic

neuritis/neuropathy)

fainting (syncope), dizziness,

tingling or numbness of hands or

feet (paraesthesia)

temporary inflammation of nerves

causing pain, paralysis and

sensitivity disorders (Guillain-

Barré syndrome [GBS])

fits (convulsions) with or without

fever

severe allergic reaction

(anaphylaxis)

temporary reduction in the

number of blood particles called

platelets (thrombocytopenia),

swollen glands in neck, armpit or

groin (lymphadenopathy)

If any of the side effects gets

serious, or if you notice any side

effects not listed in this leaflet,

please tell your doctor or

pharmacist.

Storing FluQuadri/

FluQuadri Junior

FluQuadri/FluQuadri Junior is

usually stored in the doctor's surgery

or clinic, or at the pharmacy.

However, if you need to store

FluQuadri/FluQuadri Junior:

Keep out of reach and sight of

children.

Keep FluQuadri/FluQuadri Junior

in the original pack until it is time

for it to be given.

Keep it in the refrigerator,

store at 2°C to 8°C. Do not

freeze FluQuadri/FluQuadri

Junior.

FLUQUADRI™; FLUQUADRI™ JUNIOR

Do not use FluQuadri/FluQuadri

Junior after the expiry date which

is stated on the carton after EXP.

Do not have FluQuadri/FluQuadri

Junior if the packaging is torn or

shows signs of tampering.

Medicines should not be disposed of

via wastewater or household waste.

Ask your pharmacist how to dispose

of medicines no longer required.

These measures will help to protect

the environment.

Further Information

What FluQuadri/FluQuadri

Junior contain

Ingredients

Active Ingredients:

FluQuadri/FluQuadri Junior contains

4 killed influenza virus strains:

A/Michigan/45/2015

(H1N1)pdm09-like virus (A/

Michigan/45/2015 X-275)

A/Hong Kong/4801/2014

(H3N2)-like virus (A/Hong

Kong/4801/2014 X-263B)

B/Phuket/3073/2013-like virus

(B/Phuket/3073/2013)

B/Brisbane/60/2008-like virus (B/

Brisbane/60/2008)

The other ingredients include sodium

chloride, sodium phosphate dibasic

anhydrous, sodium phosphate

monobasic anhydrous, water for

injection, and traces of formaldehyde

and octoxinol-9.

Other Ingredients:

FluQuadri contains less than 1

microgram ovalbumin (egg protein)

per dose.

FluQuadri Junior contains less than

0.5 microgram ovalbumin (egg

protein) per dose.

FluQuadri/FluQuadri Junior does not

contain any antibiotics or

preservative.

What FluQuadri/FluQuadri

Junior look like and

contents of the pack

FluQuadri is supplied in:

Prefilled syringe (clear syringe

plunger rod), 0.5 mL, for persons

36 months of age and older.

FluQuadri Junior is supplied in:

Prefilled syringe (pink syringe

plunger rod), 0.25 mL, for

persons 6 months through 35

months of age.

Name and Address of

Australian Sponsor

sanofi-aventis australia pty ltd

Talavera Corporate Centre - Building

12-24 Talavera Road

Macquarie Park NSW 2113

Australia

Tel: 1800 829 468 (1800 Vaxin8)

Name and Address of New

Zealand Sponsor

sanofi-aventis new zealand pty ltd

Level 8

56 Cawley St

Ellerslie

Auckland

New Zealand

Tel: 0800 727 838

AUST R number

AUST R 213963 (FluQuadri)

AUST R 213964 (FluQuadri Junior)

Date of preparation

5 December 2016

FLUQUADRI™; FLUQUADRI™ JUNIOR

9-11-2018

Influenza A (H1N1) 2009 Monovalent Vaccines Composition and Lot Release

Influenza A (H1N1) 2009 Monovalent Vaccines Composition and Lot Release

Vaccine lot release information updated on 3/3/2010.

FDA - U.S. Food and Drug Administration

24-10-2018

FDA approves new drug to treat influenza

FDA approves new drug to treat influenza

FDA approved Xofluza (baloxavir marboxil) to treat acute uncomplicated flu in patients 12 years old and older who have been symptomatic for less than 48 hours.

FDA - U.S. Food and Drug Administration

17-10-2018

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Published on: Tue, 16 Oct 2018 00:00:00 +0200 The duration of the vaccination campaign sufficient to eliminate lumpy skin disease (LSD) mainly depends on the vaccination effectiveness and coverage achieved. By using a spread epidemiological model, assuming a vaccination effectiveness of 65%, with 50% and 90% coverage, 3 and 4 years campaigns, respectively, are needed to eliminate LSD. When vaccination effectiveness is 80% to 95%, 2 years of vaccination at coverage of 90% is sufficient to eliminate LSD vir...

Europe - EFSA - European Food Safety Authority Publications

16-10-2018

Assessment of low pathogenic avian influenza virus transmission via raw poultry meat and raw table eggs

Assessment of low pathogenic avian influenza virus transmission via raw poultry meat and raw table eggs

Published on: Mon, 15 Oct 2018 00:00:00 +0200 A rapid qualitative assessment has been done by performing a theoretical analysis on the transmission of low pathogenic avian influenza (LPAI) via fresh meat from poultry reared or kept in captivity for the production of meat (raw poultry meat) or raw table eggs. A predetermined transmission pathway followed a number of steps from a commercial or non‐commercial poultry establishment within the EU exposed to LPAI virus (LPAIV) to the onward virus transmission...

Europe - EFSA - European Food Safety Authority Publications

28-9-2018

Avian influenza overview May – August 2018

Avian influenza overview May – August 2018

Published on: Thu, 27 Sep 2018 00:00:00 +0200 Between 16 May and 15 August 2018, three highly pathogenic avian influenza (HPAI) A(H5N8) outbreaks in poultry establishments and three HPAI A(H5N6) outbreaks in wild birds were reported in Europe. Three low pathogenic avian influenza (LPAI) outbreaks were reported in three Member States. Few HPAI and LPAI bird cases have been detected in this period of the year, in accordance with the seasonal expected pattern of LPAI and HPAI. There is no evidence to date ...

Europe - EFSA - European Food Safety Authority Publications

11-9-2018

Novel foods: a risk profile for the house cricket (Acheta domesticus)

Novel foods: a risk profile for the house cricket (Acheta domesticus)

Published on: Tue, 28 Aug 2018 00:00:00 +0200 Novel foods could represent a sustainable alternative to traditional farming and conventional foodstuffs. Starting in 2018, Regulation (EU) 2283/2015 entered into force, laying down provisions for the approval of novel foods in Europe, including insects. This Approved Regulation establishes the requirements that enable Food Business Operators to bring new foods into the EU market, while ensuring high levels of food safety for European consumers. The present ...

Europe - EFSA - European Food Safety Authority Publications

30-5-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on federal preparedness and FDA’s response efforts to the Ebola virus outbreak in the Democratic Republic of Congo

Statement from FDA Commissioner Scott Gottlieb, M.D., on federal preparedness and FDA’s response efforts to the Ebola virus outbreak in the Democratic Republic of Congo

FDA committed to helping the people of the Democratic Republic of Congo effectively confront and end the current Ebola virus outbreak

FDA - U.S. Food and Drug Administration

30-5-2018

Procleix West Nile Virus (WNV) Assay

Procleix West Nile Virus (WNV) Assay

Product approval information is indicated for the qualitative detection of West Nile Virus (WNV) RNA in plasma specimens from individual human donors, including volunteer donors of whole blood and blood components, and other living donors.

FDA - U.S. Food and Drug Administration

23-5-2018

FDA Drug Safety Communication: FDA to evaluate potential risk of neural tube birth defects with HIV medicine dolutegravir (Juluca, Tivicay, Triumeq)

FDA Drug Safety Communication: FDA to evaluate potential risk of neural tube birth defects with HIV medicine dolutegravir (Juluca, Tivicay, Triumeq)

The U.S. Food and Drug Administration (FDA) is alerting the public that serious cases of neural tube birth defects involving the brain, spine, and spinal cord have been reported in babies born to women treated with dolutegravir (Juluca, Tivicay, Triumeq) used to treat human immunodeficiency virus (HIV).

FDA - U.S. Food and Drug Administration

19-4-2018

Fluad trivalent influenza vaccine

Fluad trivalent influenza vaccine

Safety advisory - risk to patients with latex allergy

Therapeutic Goods Administration - Australia

27-3-2018

Flu vaccine: 2018 seasonal influenza vaccines for use in children

Flu vaccine: 2018 seasonal influenza vaccines for use in children

Information about influenza vaccines for use in 2018

Therapeutic Goods Administration - Australia

30-8-2018

Fluenz Tetra (AstraZeneca AB)

Fluenz Tetra (AstraZeneca AB)

Fluenz Tetra (Active substance: influenza vaccine (live attenuated, nasal)) - Centralised - Variation - Commission Decision (2018)5815 of Thu, 30 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2617/II/82

Europe -DG Health and Food Safety

22-8-2018

BTVPUR (Merial)

BTVPUR (Merial)

BTVPUR (Active substance: Bluetongue virus vaccine (inactivated) (multistrain: 1-2 strains out of a set of 4)) - Centralised - 2-Monthly update - Commission Decision (2018)5630 of Wed, 22 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/2231/II/10

Europe -DG Health and Food Safety

7-8-2018

Intanza (Sanofi Pasteur Europe)

Intanza (Sanofi Pasteur Europe)

Intanza (Active substance: Influenza Vaccine (split virion, inactivated)) - Centralised - Withdrawal - Commission Decision (2018)5426 of Tue, 07 Aug 2018

Europe -DG Health and Food Safety

3-8-2018

EU/3/18/2042 (MeiraGTx UK II Limited)

EU/3/18/2042 (MeiraGTx UK II Limited)

EU/3/18/2042 (Active substance: Adenovirus associated viral vector serotype 2/8 containing the human CNGA3 gene) - Orphan designation - Commission Decision (2018)5274 of Fri, 03 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/048/18

Europe -DG Health and Food Safety

30-7-2018

Zalmoxis (MolMed S.p.A.)

Zalmoxis (MolMed S.p.A.)

Zalmoxis (Active substance: Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (?LNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)) - Centralised - Renewal - Commission Decision (2018)5118 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2801/R/10

Europe -DG Health and Food Safety

25-7-2018

Respiporc Flu3 (IDT Biologika GmbH)

Respiporc Flu3 (IDT Biologika GmbH)

Respiporc Flu3 (Active substance: Inactivated vaccine against swine influenza in pigs) - Centralised - Yearly update - Commission Decision (2018)4991 of Wed, 25 Jul 2018

Europe -DG Health and Food Safety

11-7-2018

Hiprabovis IBR Marker Live (Laboratorios Hipra, S.A.)

Hiprabovis IBR Marker Live (Laboratorios Hipra, S.A.)

Hiprabovis IBR Marker Live (Active substance: Live gE- tk- double-gene deleted Bovine Herpes Virus type 1 (BoHV-1), strain CEDDEL) - Centralised - Yearly update - Commission Decision (2018)4520 of Wed, 11 Jul 2018

Europe -DG Health and Food Safety

4-7-2018

ERYSENG PARVO (Laboratorios Hipra, S.A.)

ERYSENG PARVO (Laboratorios Hipra, S.A.)

ERYSENG PARVO (Active substance: Inactivated porcine parvovirus, strain NADL-2 / Inactivated Erysipelothrix rhusiopathiae, strain R32E11) - Centralised - Yearly update - Commission Decision (2018) 4354 of Wed, 04 Jul 2018

Europe -DG Health and Food Safety

29-6-2018

Porcilis PCV M Hyo (Intervet International B.V.)

Porcilis PCV M Hyo (Intervet International B.V.)

Porcilis PCV M Hyo (Active substance: Porcine circovirus and Mycoplasma hyopneumoniae vaccine (inactivated)) - Centralised - 2-Monthly update - Commission Decision (2018)4166 of Fri, 29 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/3796/II/7

Europe -DG Health and Food Safety

19-6-2018

Aftovaxpur Doe (Merial)

Aftovaxpur Doe (Merial)

Aftovaxpur Doe (Active substance: purified, inactivated foot-and-mouth disease virus strains O1 Manisa, O1 BFS, O Taiwan 3/97, A22 Iraq, A24 Cruzeiro, A Turkey 14/98, Asia 1 Shamir, SAT2 Saudi Arabia) - Centralised - Renewal - Commission Decision (2018)3891 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/2292/R/8

Europe -DG Health and Food Safety

1-6-2018

BTVPUR AlSap 2-4 (Merial)

BTVPUR AlSap 2-4 (Merial)

BTVPUR AlSap 2-4 (Active substance: Bluetongue Virus Serotype 2 antigen - Bluetongue Virus Serotype 4 antigen) - Withdrawal (sunset clause) - No Commission Decision

Europe -DG Health and Food Safety

29-5-2018

EU/3/18/2027 (Regeneron Ireland U.C.)

EU/3/18/2027 (Regeneron Ireland U.C.)

EU/3/18/2027 (Active substance: Three human monoclonal antibodies against the Ebola virus glycoprotein) - Orphan designation - Commission Decision (2018)3395 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/008/18

Europe -DG Health and Food Safety

16-5-2018

BTVPUR AlSap 8 (Merial)

BTVPUR AlSap 8 (Merial)

BTVPUR AlSap 8 (Active substance: Bluetongue virus Serotype 8 Antigen) - Centralised - Withdrawal - Commission Decision (2018)3018 of Wed, 16 May 2018

Europe -DG Health and Food Safety

16-5-2018

BTVPUR AlSap 1 (Merial)

BTVPUR AlSap 1 (Merial)

BTVPUR AlSap 1 (Active substance: Bluetongue Virus Serotype 1 antigen) - Centralised - Withdrawal - Commission Decision (2018)3017 of Wed, 16 May 2018

Europe -DG Health and Food Safety

15-5-2018

Aflunov (Seqirus S.r.l.)

Aflunov (Seqirus S.r.l.)

Aflunov (Active substance: Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)) - Centralised - Yearly update - Commission Decision (2018)3066 of Tue, 15 May 2018

Europe -DG Health and Food Safety

18-4-2018

EU/3/18/2012 (IDEA Innovative Drug European Associates Limited)

EU/3/18/2012 (IDEA Innovative Drug European Associates Limited)

EU/3/18/2012 (Active substance: Genetically modified replication-incompetent herpes simplex virus-1 expressing collagen VII) - Orphan designation - Commission Decision (2018)2408 of Wed, 18 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/244/17

Europe -DG Health and Food Safety

9-2-2018

Suvaxyn Circo (Zoetis Belgium S.A.)

Suvaxyn Circo (Zoetis Belgium S.A.)

Suvaxyn Circo (Active substance: Porcine circovirus vaccine (inactivated, recombinant)) - New authorisation - Commission Decision (2018)861 of Fri, 09 Feb 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/4242

Europe -DG Health and Food Safety